Nuformix advances NXP002 programme with £168,750 Placing

Nuformix plc, a pharmaceutical company focusing on fibrosis and oncology through drug repurposing, presents its audited results and strategic priorities for 2024.

Nuformix plc targets fibrosis and oncology needs with NXP002. Company applies for Orphan Drug Designation in Europe for novel IPF treatment.

Nuformix plc targets medical needs in fibrosis and oncology. The company has submitted a draft application for an Orphan Drug Designation with the EMA.

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the six months ended 31 March 2024. Operational highlights (including post-period end) ·    The Board continues

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its audited results for the eighteen months ended 30 September 2023 following the change in the Company’s accounting reference

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company has achieved the second milestone according to its updated NXP001 exclusive licensing agreement with Oxilio

Nuformix plc (LON: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that it has been issued with an Official Decision to Grant Notice of Allowance for Japanese National Phase

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company is to receive new immediate and near-term undisclosed milestone payments as part of an update

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the appointment of Kreston Reeves LLP as auditor to the Company. The appointment of Kreston Reeves

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the twelve months ended 31 March 2023 following the change in the Company’s accounting

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced a subscription to raise gross proceeds of £70,000 through a subscription for 35,000,000 new ordinary shares